$84.98 1.8 2.2%
Last Trade - 26/02/21
| Market Cap | ÂŁ3.66bn |
| Enterprise Value | ÂŁ3.82bn |
| Revenue | ÂŁ20.5m |
| Position in Universe | 1354th / 6715 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020E | 2021E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 54.0 | 249.4 | |||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. The Company's glutamate platform includes three clinical-stage product candidates being developed for the treatment of various neurological indications: trigriluzole for the treatment of obsessive-compulsive disorder (OCD), spinocerebellar ataxia (SCA) and Alzheimer's disease; BHV-0223 for the treatment of amyotrophic lateral sclerosis (ALS), and BHV-5000 for the treatment of neurological and psychiatric illnesses such as Rett syndrome, neuropathic pain and treatment-resistant depression. BHV-0223 is developing for the treatment of ALS, a neurodegenerative disease that affects nerve cells in the brain and spinal cord. The Company also develops bispecific compounds that is designed to emulate or enhance the activity of biologics.
| Last Annual | December 31st, 2019 |
| Last Interim | September 30th, 2020 |
| Incorporated | September 25, 2013 |
| Public Since | May 4, 2017 |
| No. of Shareholders: | 57 |
| No. of Employees: | 647 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | |
| Exchange | New York Stock Exchange |
| Shares in Issue | 59,939,166 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 215 Church St, NEW HAVEN, 06510-1803, United States |
| Web | http://biohavenpharma.com/ |
| Phone | +1 203 4040410 |
| Contact | () |
| Auditors | PricewaterhouseCoopers LLP |
As of 26/02/21, shares in Biohaven Pharmaceutical Holding are trading at $84.98, giving the company a market capitalisation of ÂŁ3.66bn. This share price information is delayed by 15 minutes.
Shares in Biohaven Pharmaceutical Holding are currently trading at $84.98 and the price has moved by 0.108k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Biohaven Pharmaceutical Holding price has moved by 60.61% over the past year.
Of the analysts with advisory recommendations for Biohaven Pharmaceutical Holding, there are there are currently 4 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Biohaven Pharmaceutical Holding is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Biohaven Pharmaceutical Holding is scheduled to issue upcoming financial results on the following dates:
Biohaven Pharmaceutical Holding does not currently pay a dividend.
Biohaven Pharmaceutical Holding does not currently pay a dividend.
Biohaven Pharmaceutical Holding does not currently pay a dividend.
To buy shares in Biohaven Pharmaceutical Holding you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Biohaven Pharmaceutical Holding are currently trading at $84.98, giving the company a market capitalisation of ÂŁ3.66bn.
Here are the trading details for Biohaven Pharmaceutical Holding:
Based on an overall assessment of its quality, value and momentum, Biohaven Pharmaceutical Holding is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Biohaven Pharmaceutical Holding are currently priced at $84.98. At that level they are trading at 0.61% discount to the analyst consensus target price of 0.00.
Analysts covering Biohaven Pharmaceutical Holding currently have a consensus Earnings Per Share (EPS) forecast of -12.352 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biohaven Pharmaceutical Holding. Over the past six months, the relative strength of its shares against the market has been 28.91%. At the current price of $84.98, shares in Biohaven Pharmaceutical Holding are trading at 13.38% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Biohaven Pharmaceutical Holding.
Biohaven Pharmaceutical Holding's management team is headed by:
Here are the top five shareholders of Biohaven Pharmaceutical Holding based on the size of their shareholding:
